Manlio Cipriani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2697264/publications.pdf

Version: 2024-02-01

516710 361022 1,325 41 16 35 citations g-index h-index papers 46 46 46 1676 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Prevalence, Characteristics, and Outcomes of COVID-19–Associated Acute Myocarditis. Circulation, 2022, 145, 1123-1139.	1.6	118
2	Update on acute myocarditis. Trends in Cardiovascular Medicine, 2021, 31, 370-379.	4.9	66
3	Early intra-aortic balloon pump in acute decompensated heart failure complicated by cardiogenic shock: Rationale and design of the randomized Altshock-2 trial. American Heart Journal, 2021, 233, 39-47.	2.7	15
4	Postâ€discharge arrhythmic risk stratification of patients with acute myocarditis and lifeâ€threatening ventricular tachyarrhythmias. European Journal of Heart Failure, 2021, 23, 2045-2054.	7.1	17
5	ANMCO POSITION PAPER: Use of sacubitril/valsartan in hospitalized patients with acute heart failure. European Heart Journal Supplements, 2021, 23, C176-C183.	0.1	2
6	Allogeneic peripheral blood stem cell transplantation and accelerated atherosclerosis: An intriguing association needing targeted surveillance. Lessons from a rare case of acute anterior myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2020, 9, NP3-NP7.	1.0	4
7	Psychological outcomes of left ventricular assist device longâ€term treatment: A 2â€year followâ€up study. Artificial Organs, 2020, 44, 67-71.	1.9	12
8	Fulminant myocarditis triggered by OC43 subtype coronavirus: a disease deserving evidence-based care bundles. Journal of Cardiovascular Medicine, 2020, 21, 529-531.	1.5	21
9	Viral genome search in myocardium of patients with fulminant myocarditis. European Journal of Heart Failure, 2020, 22, 1277-1280.	7.1	19
10	Fulminant Versus Acute Nonfulminant Myocarditis in Patients With LeftÂVentricular SystolicÂDysfunction. Journal of the American College of Cardiology, 2019, 74, 299-311.	2.8	148
11	Recurrent cardiac sarcoidosis after heart transplantation. Clinical Research in Cardiology, 2019, 108, 1171-1173.	3.3	2
12	Response by Ammirati et al to Letter Regarding Article, "Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis― Circulation, 2019, 139, 1346-1347.	1.6	1
13	Cardiogenic shock: old and new circulatory assist devices: the role of counter-pulsation. European Heart Journal Supplements, 2019, 21, B59-B60.	0.1	3
14	Persistent left ventricular dysfunction after acute lymphocytic myocarditis: Frequency and predictors. PLoS ONE, 2019, 14, e0214616.	2.5	18
15	Safety of centrifugal left ventricular assist device in patients previously treated with MitraClip system. International Journal of Cardiology, 2019, 283, 131-133.	1.7	15
16	Coping, Mood, Quality of Life, and Outcomes in Recipients of Left Ventricular Assist Devices: A Cluster Analysis. Psychosomatic Medicine, 2019, 81, 192-199.	2.0	13
17	Singleâ€center outbreak of <i>Pneumocystis jirovecii</i> pneumonia in heart transplant recipients. Transplant Infectious Disease, 2018, 20, e12880.	1.7	16
18	Response by Ammirati et al to Letter Regarding Article, "Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis― Circulation, 2018, 137, 1427-1428.	1.6	1

#	Article	IF	Citations
19	Fulminant myocarditis: Characteristics, treatment, and outcomes. Anatolian Journal of Cardiology, 2018, 19, 279-286.	0.9	55
20	Acute and Fulminant Myocarditis: a Pragmatic Clinical Approach to Diagnosis and Treatment. Current Cardiology Reports, 2018, 20, 114.	2.9	72
21	Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis. Circulation, 2018, 138, 1088-1099.	1.6	253
22	Antithrombotic therapy in ventricular assist device (VAD) management: From ancient beliefs to updated evidence. A narrative review. IJC Heart and Vasculature, 2018, 20, 20-26.	1.1	10
23	Not every fulminant lymphocytic myocarditis fully recovers. Journal of Cardiovascular Medicine, 2018, 19, 453-454.	1.5	11
24	HeartWare-HVAD for end-stage heart failure: a review of clinical experiences with ≥50 patients. Expert Review of Medical Devices, 2017, 14, 423-437.	2.8	2
25	Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis. Circulation, 2017, 136, 529-545.	1.6	182
26	Refractory ventricular tachycardia caused by inflow cannula mechanical injury in a patient with left ventricular assist device: Catheter ablation and pathological findings. Journal of Arrhythmia, 2017, 33, 494-496.	1.2	5
27	Quantitative changes in late gadolinium enhancement at cardiac magnetic resonance in the early phase of acute myocarditis. International Journal of Cardiology, 2017, 231, 216-221.	1.7	44
28	Prognostic impact of late gadolinium enhancement in the risk stratification of heart transplant patients. European Heart Journal Cardiovascular Imaging, 2017, 18, 130-137.	1.2	25
29	New concepts in fulminant myocarditis and risk of cardiac mortality. Oncotarget, 2017, 8, 84624-84625.	1.8	7
30	Women with nonischemic cardiomyopathy have a favorable prognosis and a better left ventricular remodeling than men after cardiac resynchronization therapy. Journal of Cardiovascular Medicine, 2016, 17, 291-298.	1.5	9
31	Ticagrelor for left ventricular assist device thrombosis: A new therapeutic option to be evaluated with caution. International Journal of Cardiology, 2016, 221, 58-59.	1.7	4
32	Prognostic implications of mitral regurgitation in patients after cardiac resynchronization therapy. European Journal of Heart Failure, 2016, 18, 1060-1068.	7.1	30
33	A life-threatening presentation of eosinophilic granulomatosis with polyangiitis. Journal of Cardiovascular Medicine, 2016, 17, e109-e111.	1.5	11
34	Cumulative analysis on 4802 patients confirming that women benefit more than men from cardiac resynchronization therapy. International Journal of Cardiology, 2015, 182, 454-456.	1.7	4
35	Left ventricular or Bi-ventricular assist device? How dobutamine stress echocardiography can untie the dilemma of right ventricular dysfunction. International Journal of Cardiology, 2014, 177, e6-e8.	1.7	2
36	Levosimendan reverted severe pulmonary hypertension in one patient on waiting list for heart transplantation. International Journal of Cardiology, 2013, 168, 4518-4519.	1.7	4

3

#	Article	IF	CITATIONS
37	Late gadolinium enhancement patterns on cardiac magnetic resonance images in heart transplant patients. Journal of Cardiovascular Magnetic Resonance, 2010, 12, .	3.3	O
38	Value of transthoracic two-dimensional echocardiography in predicting viability in patients with healed Q-wave anterior wall myocardial infarction. American Journal of Cardiology, 1995, 76, 1002-1006.	1.6	36
39	Imaging the left anterior descending coronary artery by high-frequency transthoracic echocardiography in heart transplant patients. American Journal of Cardiology, 1995, 75, 855-858.	1.6	13
40	Transthoracic High-Frequency Echocardiographic Detection of Atherosclerotic Lesions in the Descending Portion of the Left Coronary Artery. Journal of the American Society of Echocardiography, 1993, 6, 290-298.	2.8	19
41	Value of negative predischarge exercise testing in identifying patients at low risk after acute myocardial infarction treated by systemic thrombolysis. American Journal of Cardiology, 1992, 70, 31-33.	1.6	32